Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 181.59 Million SEK | 99.49% |
| 2022 | 91.03 Million SEK | -60.16% |
| 2021 | 228.5 Million SEK | -38.22% |
| 2020 | 369.85 Million SEK | 88.25% |
| 2019 | 196.47 Million SEK | 52.66% |
| 2018 | 128.69 Million SEK | 108.19% |
| 2017 | 61.81 Million SEK | 111.01% |
| 2016 | 29.29 Million SEK | 318.39% |
| 2015 | 7 Million SEK | 26.91% |
| 2014 | 5.51 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 259.95 Million SEK | 24.91% |
| 2024 Q1 | 208.11 Million SEK | 14.6% |
| 2023 Q2 | 178.86 Million SEK | 102.2% |
| 2023 Q3 | 161.58 Million SEK | -9.67% |
| 2023 Q4 | 181.59 Million SEK | 12.39% |
| 2023 Q1 | 88.46 Million SEK | -2.82% |
| 2023 FY | 181.59 Million SEK | 99.49% |
| 2022 Q3 | 95.74 Million SEK | 5.44% |
| 2022 Q1 | 141.93 Million SEK | -37.88% |
| 2022 Q2 | 90.8 Million SEK | -36.03% |
| 2022 FY | 91.03 Million SEK | -60.16% |
| 2022 Q4 | 91.03 Million SEK | -4.92% |
| 2021 FY | 228.5 Million SEK | -38.22% |
| 2021 Q4 | 228.5 Million SEK | 6.09% |
| 2021 Q3 | 215.38 Million SEK | -18.34% |
| 2021 Q2 | 263.75 Million SEK | -25.63% |
| 2021 Q1 | 354.67 Million SEK | -4.11% |
| 2020 Q2 | 272.12 Million SEK | 69.79% |
| 2020 Q4 | 369.85 Million SEK | 47.83% |
| 2020 Q3 | 250.19 Million SEK | -8.06% |
| 2020 Q1 | 160.27 Million SEK | -18.43% |
| 2020 FY | 369.85 Million SEK | 88.25% |
| 2019 Q1 | 126.49 Million SEK | -1.71% |
| 2019 Q3 | 150.75 Million SEK | -30.26% |
| 2019 Q4 | 196.47 Million SEK | 30.33% |
| 2019 FY | 196.47 Million SEK | 52.66% |
| 2019 Q2 | 216.18 Million SEK | 70.9% |
| 2018 Q1 | 87 Million SEK | 40.75% |
| 2018 Q3 | 131.96 Million SEK | -0.16% |
| 2018 FY | 128.69 Million SEK | 108.19% |
| 2018 Q4 | 128.69 Million SEK | -2.48% |
| 2018 Q2 | 132.17 Million SEK | 51.92% |
| 2017 Q1 | 47.23 Million SEK | 61.23% |
| 2017 Q4 | 61.81 Million SEK | 22.17% |
| 2017 Q3 | 50.59 Million SEK | -19.12% |
| 2017 Q2 | 62.56 Million SEK | 32.46% |
| 2017 FY | 61.81 Million SEK | 111.01% |
| 2016 Q4 | 29.29 Million SEK | 0.0% |
| 2016 FY | 29.29 Million SEK | 318.39% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 7 Million SEK | 26.91% |
| 2014 FY | 5.51 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -70.363% |
| Ziccum AB (publ) | 6.38 Million SEK | -2742.799% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -7598.092% |
| BioArctic AB (publ) | 139.5 Million SEK | -30.175% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -424.804% |
| Mendus AB (publ) | 51.22 Million SEK | -254.51% |
| Genovis AB (publ.) | 98.04 Million SEK | -85.215% |
| Intervacc AB (publ) | 21.68 Million SEK | -737.629% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -579.939% |
| Active Biotech AB (publ) | 13.4 Million SEK | -1255.209% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -46.475% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -1026.748% |
| Aptahem AB (publ) | 8.99 Million SEK | -1918.243% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -344.45% |
| Kancera AB (publ) | 17.97 Million SEK | -910.112% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -293.239% |
| Fluicell AB (publ) | 8.91 Million SEK | -1936.994% |
| Saniona AB (publ) | 86.08 Million SEK | -110.957% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -3420.706% |
| Biovica International AB (publ) | 34.76 Million SEK | -422.329% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -1456.376% |
| AcouSort AB (publ) | 10.37 Million SEK | -1649.836% |
| Xintela AB (publ) | 14.01 Million SEK | -1195.74% |
| Abliva AB (publ) | 16.78 Million SEK | -982.164% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 15.378% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -1469.695% |
| OncoZenge AB (publ) | 1.69 Million SEK | -10588.523% |
| Amniotics AB (publ) | 10.54 Million SEK | -1621.798% |
| 2cureX AB (publ) | 2.93 Million SEK | -6087.325% |
| CombiGene AB (publ) | 4.15 Million SEK | -4269.539% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -4002.982% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 88.402% |
| Camurus AB (publ) | 414.81 Million SEK | 56.222% |
| Corline Biomedical AB | 6.78 Million SEK | -2574.886% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -195.969% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -847.6% |
| I-Tech AB | 16.2 Million SEK | -1020.63% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 84.687% |
| Cyxone AB (publ) | 4.69 Million SEK | -3768.726% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -1262.53% |
| Biosergen AB | 5.08 Million SEK | -3471.249% |
| Cantargia AB (publ) | 54.97 Million SEK | -230.358% |
| NextCell Pharma AB | 13.68 Million SEK | -1226.593% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -152.746% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -1218.644% |
| Nanologica AB (publ) | 79.32 Million SEK | -128.923% |
| SynAct Pharma AB | 51.83 Million SEK | -250.345% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -2184.539% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -3395.669% |
| LIDDS AB (publ) | 3.75 Million SEK | -4734.878% |
| Lipum AB (publ) | 7.53 Million SEK | -2309.101% |
| BioInvent International AB (publ) | 90.45 Million SEK | -100.765% |
| Alzinova AB (publ) | 9.33 Million SEK | -1846.179% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -10022.52% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -881.929% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -4631.579% |
| Simris Alg AB (publ) | 148.93 Million SEK | -21.929% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -155.347% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 62.338% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -1324.969% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -2401.35% |